Association analysis of PPARγ (p.Pro12Ala) polymorphism with type 2 diabetic retinopathy in patients from north India

References

• International Diabetes Federation. The diabetes atlas. 4th edn. Brussels: Author, 2009.
   Google Scholar
• Ma J, Li Y, Zhou F, et al. Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene and diabetic retinopathy in Caucasians and Asians. Mol Vis 2012;18:2352–2360.
   PubMed Web of Science ®Google Scholar
• Reema M, Pardeepa R. Diabetic retinopathy: an Indian perspective. Indian J Med Res 2007;125:297–310.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520–526.
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM, Al-Mezaine HS, Ola MS. Pathophysiology and management of diabetic retinopathy. Expert Rev Ophthalmol 2009;4:627–647.
   Google Scholar
• Francis GA, Fayard E, Picard F, et al. Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003;65:261–311.
   PubMed Web of Science ®Google Scholar
• Uthra S, Raman R, Mukesh BN, et al. Genetics of diabetic retinopathy. Int J Hum Genet 2008;8:155–159.
   Web of Science ®Google Scholar
• Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999;4:611–617.
   PubMed Web of Science ®Google Scholar
• Tawfik A, Sanders T, Kahook K, et al. Suppression of retinal peroxisome proliferator-activated receptor γ in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase. Invest Ophthalmol Visual Sci 2009;50:878–884.
   PubMed Web of Science ®Google Scholar
• Ciudin A, Hernandez C, Simo R. Molecular implications of the PPARs in the diabetic eye. PPAR Res 2013;2013:1–11.
   Web of Science ®Google Scholar
• Elbrecht A, Chen Y, Cullinan CA, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptor γ 1 and γ 2. Biochem Biophys Res Commun 1996;224:431–437.
   PubMed Web of Science ®Google Scholar
• Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation. Biochem Biophys Res Commun 1997;241:270–274.
   PubMed Web of Science ®Google Scholar
• Yilmaz-Aydogan H, Kurnaz O, Kurt O, et al. Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without type 2 diabetes. Mol Cell Biochem 2011;358:355–363.
   PubMed Web of Science ®Google Scholar
• Pollex RL, Mamakeesick M, Zinman B, et al. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Comp 2006;21:166–171.
   Web of Science ®Google Scholar
• Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004;5:899–918.
   Web of Science ®Google Scholar
• Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Visual Sci 1998;39:233–252.
   PubMed Web of Science ®Google Scholar
• Henricsson M, Nilsson A, Groop L, et al. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycemic control. Acta Ophthalmol Scand 1996;74:523–527.
   PubMedGoogle Scholar
• Dowse GK, Humphrey AR, Collins VR, et al. Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. Am J Epidemiol 1998;147:448–457.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Parrinello G, Cancarini A, et al. Predicting the risk of diabetic retinopathy in type 2 diabetic patients. J Diabetes Comp 2011;25:292–297.
   PubMed Web of Science ®Google Scholar
• El-Haddad OA, Saad MK. Prevalence and risk factors for diabetic retinopathy among Omani diabetics. Br J Ophthalmol 1998;82:901–906.
   PubMed Web of Science ®Google Scholar
• Ozmen B, Boyvada S. The relationship between self monitoring of blood glucose control and glycosylated haemoglobin in patients with type 2 diabetes with and without diabetic retinopathy. J Diabetes Comp 2003;17:128–134.
   PubMed Web of Science ®Google Scholar
• Zavrelova H, Hoekstra T, Alesseme M, et al. Progression and regression: direct developmental pattern of diabetic retinopathy in patients with type 2 diabetes treated in the diabetes care system West-Priestland, The Netherlands. Diabetes Care 2011;34:867–872.
   PubMed Web of Science ®Google Scholar
• Petrovic MG, Kunej T, Peterlin B, et al. Gly482Ser polymorphism of the peroxisome proliferator activated receptor-γ coactivator-1 gene might be a risk factor for diabetic retinopathy in Slovene population (Caucasians) with type 2 diabetes and the Pro12Ala polymorphism of the PPARγ gene is not. Diabetes Metab Res Rev 2005;21:470–474.
   PubMed Web of Science ®Google Scholar
• Costa V, Casamassimi A, Esposito K, et al. Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in Italy. J Biomed Biotechnol 2008;2009:1–7.
   Google Scholar
• Malecki MT, Cyganek K, Mirkiewicz-Sieradzka B, et al. Alanine variant of the Pro12Ala polymorphism of the PPAR gamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes. Diabetes Res Clin Pract 2008;80:139–145.
   PubMed Web of Science ®Google Scholar
• Tariq K, Malik SB, Ali SH, et al. Association of Pro12Ala polymorphism in peroxisome proliferator activated receptor gamma with proliferative diabetic retinopathy. Mol Vis 2013;19:710–717.
   PubMed Web of Science ®Google Scholar
• Ereqat S, Nasereddin A, Azmi K, et al. Impact of the Pro12Ala polymorphism of the PPAR-Gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients. PPAR Res 2009;2009:1–5.
   Web of Science ®Google Scholar
• Bhatt SP, Misra A, Sharma M, et al. Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians. Diabetes Technol Ther 2012;14:828–834.
   PubMed Web of Science ®Google Scholar
• Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, et al. Ala12Ala genotype of the peroxisome proliferator-activated receptor γ2 protects against atherosclerosis. J Clin Endocrinol Metab 2004;89:4238–4242.
   PubMed Web of Science ®Google Scholar
• Liu L, Zheng T, Wang F, et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 2010;33:144–149.
   PubMed Web of Science ®Google Scholar
• Hermann S, Ringel J, Wang J, et al. Peroxisome proliferator-activated receptor- γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. Diabetes 2002;51:2653–2657.
   PubMed Web of Science ®Google Scholar
• Caramori ML, Canani LH, Costa LA, et al. The human peroxisome proliferator-activated receptor γ2 (PPARγ2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003;52:3010–3013.
   PubMed Web of Science ®Google Scholar